IP Library › Granted Patent US 10,245,313
Granted Patent B2
US 10,245,313 · App. 14/921,323 · Granted Apr 2, 2019

DNA motif compounds and methods for inducing specific antibodies and cellular immunity

Inventors: Zhiwei Chen (Hong Kong, CN); Xilin Wu (Hong Kong, CN); Zhiwei Wu (Nanjing, CN)
Assignees: VERSITECH LIMITED; NANJING UNIVERSITY
A61K39/21A61K39/12A61K2039/53A61K2039/575C12N2740/16034C12N2740/16234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,245,313
App. No.
14/921,323
Granted
Apr 2, 2019
Kind
B2
Abstract

The present invention relates to the field of applied immunotechnology and medicine. More specifically, it relates to DNA motif vaccine design, glyco-DNA motif vaccine design, and immunogen design for producing antibodies against an epitope of arbitrary sequences or polysaccharide epitope, particularly those epitopes against which it is otherwise very difficult to induce antibodies, such as those of HIV-1. The present invention also relates to immunogen design to induce robust cellular and humoral immunity.

Claims (10)

1. An immunogenic composition comprising:

a mixture of different plasmids, each of which encodes a motif peptide comprising the sequence xxxxxNCSFNITTxxxx (SEQ ID NO: 1), wherein x stands for any amino acid residue, and wherein the x residues flanking NCSFNITT motif are different when compared to another plasmid in the mixture.

2. The immunogenic composition of claim 1 , wherein the motif peptide is modified to add host-derived carbohydrates on an amino acid residue of Asparagine (N).

3. The immunogenic composition of claim 1 , further comprising a sequence consisting of SEQ ID NO: 13.

4. The immunogenic composition of claim 1 , wherein the plasmids are PD1-p24 plasmids with a pVAX backbone.

5. A method of inducing an immune response in a patient comprising administering the immunogenic composition of claim 1 .

6. A kit comprising a therapeutically effective amount of the immunogenic composition of claim 1 .

7. The kit of claim 6 , further comprising a sequence consisting of SEQ ID NO: 13.

8. The immunogenic composition of claim 1 , further comprising one or more primers selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 18, and 19.

9. The kit of claim 6 , wherein the kit further comprises one or more primers selected from the group consisting of SEQ ID NO: 14, 15, 16, 17, 18, and 19.

Assignments (2)
CHANGE OF NAME Recorded Apr 13, 2026
From: VERSITECH LIMITED
To: UNIVERSITY OF HONG KONG VERSITECH LIMITED
Reel/Frame 075384/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2018
From: WU, ZHIWEI
To: NANJING UNIVERSITY
Reel/Frame 047686/0495 →
Continuity (2)
Provisional Application 62068316 · Oct 24, 2014
Related Publication 20160114028A1 · Apr 28, 2016